> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CDC Panel Recommends Resumption of J&J Vacine
- URL: https://www.fdaweb.com/cdc-panel-recommends-resumption-of-j-j-vacine/
- Published: 2021-04-23T12:00:00.000Z
- Updated: 2026-09-14T16:56:07.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5149183

**A CDC advisory committee 4/23 voted (10 to 4) to recommend that the U.S. resume vaccinations with Johnson & Johnson’s Covid-19 vaccine. Its use was paused earlier this month (**[**see earlier story**](https://www.fdaweb.com/fda-cdc-urge-pause-in-j-j-vaccination/)**) to review safety data in the wake of rare blood clot reports. Panel members also recommended that FDA include a warning about rare clotting in women under 50\. The panel came to its recommendation after reviewing 15 cases of blood clots reported in almost 8 million J&J vaccinations. Earlier this week, a similar European Medicines Agency (EMA)** [**safety review**](https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood?ref=fdaweb.com) **said the vaccine continues to have a favorable benefit-risk profile but it should carry a warning in its product information about rare and unusual blood clots with low blood platelets.**